The approval of fezolinetant and the expanding NK3 receptor antagonist class have added a meaningful non-hormonal option to the clinical toolkit for vasomotor symptom management — but translating the trial data into practice raises real questions. In this session, Dr. Jill Liss delivers a clinical update on the current NKT landscape: mechanism of action, efficacy and safety data, patient selection criteria, and practical considerations for prescribing. Particular attention will be given to populations where non-hormonal options are most clinically relevant, including patients with hormone-sensitive cancer histories and those who prefer or require non-estrogen-based management.

Jill Liss, MD, MSCP, FACOG, is an Associate Clinical Professor of Obstetrics and Gynecology and Director of OBGYN Undergraduate Medical Education at the University of Colorado School of Medicine, where she also serves as Co-Director of Gynecology for the CU Integrated Transgender Program. Her clinical expertise centers on menopause management, gender-diverse gynecologic care, and abnormal uterine bleeding. Dr. Liss is a peer-reviewed author and Principal Investigator in clinical trials, with publications including work on compounded bioidentical hormones, menopause and sexual health, and the state of menopause education in medical training. She serves as a reviewer for the journal Menopause and was recognized as a Scholar and Leader by the Association of Professors in Gynecology and Obstetrics. She is an active member of The Menopause Society and the World Professional Association for Transgender Health.